METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Matched conditions: METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Radiation boost may improve immunotherapy for advanced head and neck cancer
Disease control OngoingThis study compares two treatments for head and neck cancer that has spread to other parts of the body. All participants receive immunotherapy (pembrolizumab) plus chemotherapy, then half also get targeted radiation. The goal is to see if adding radiation helps people live longer…
Matched conditions: METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Promising combo targets Hard-to-Treat head and neck cancer
Disease control OngoingThis study tests a combination of an immunotherapy drug (cemiplimab) and two low-dose chemotherapy drugs (paclitaxel and carboplatin) in people with head and neck cancer that has returned or spread. The goal is to see if this mix can shrink tumors better than standard treatments.…
Matched conditions: METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC